Quantification of Errors in Ordinal Outcome Scales Using Shannon Entropy: Effect on Sample Size Calculations

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Mandava, Pitchaiah ^a,b   Krumpelman, Chase S ^b   Shah, Jharna N ^b   White, Donna L ^a   Kent, Thomas A ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISUFENTON SODIUM; ENLIMOMAB; ETHYLENEGLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID BIS(2 OCTYLOXYETHYL) ESTER; MINOCYCLINE; NORPHENAZONE; PLACEBO;

ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; ERROR; HUMAN; INFORMATION SCIENCE; INTERRATER RELIABILITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANKIN SCALE; SAMPLE SIZE; SHANNON ENTROPY; UNCERTAINTY;

BIAS (EPIDEMIOLOGY); HUMANS; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE; STROKE;

EID: 84879832524     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067754     Document Type: Article

References (73)

1. Quinn TJ, Dawson J, Walters MR, Lees KR, (2009) Functional outcome measures in contemporary stroke trials. Int J Stroke 4: 200-205.
2. Tilley BC, Marler J, Geller N, Lu M, Legler J, et al. (1996) Using a global test for multiple outcomes in stroke trials with application to the NINDS t-PA Stroke Trial. Stroke 27: 2136-2141.
3. Vahedi K, Vicaut E, Mateo J, Kurtz A, Orabi M, et al. (2007) Sequential-design, multicenter, randomized, controlled trial of early decompressive craniectomy in malignant middle cerebral artery infarction (DECIMAL Trial). Stroke 38: 2506-2517.
4. Jüttler E, Schwab S, Schmiedek P, Unterberg A, Hennerici M, et al. (2007) Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY): a randomized, controlled trial. Stroke 38: 2518-2525.
5. Hofmeijer J, Kappelle LJ, Algra A, Amelink GJ, van Gijn J, et al. (2009) Surgical decompression for space-occupying cerebral infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening Edema Trial [HAMLET]): a multicentre, open, randomised trial. The Lancet Neurol 8: 326-333.
6. Points to consider on clinical investigation of medicinal products for the treatment of acute stroke. The European Agency for the Evaluation of Medicinal Products (2001) Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003342.pdf.Accessed 2013 May 29.
7. Whitehead J, (1993) Sample size calculations for ordered categorical data. Statistics in Medicine 1993 12: 2257-2271.
8. Campbell MJ, Julious SA, Altman DG, (1995) Estimating sample sizes for binary, Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ 311: 1145-1148.
9. Tilley BC, (2012) Contemporary outcome measures in acute stroke research. Stroke 43: 935-937.
10. Savitz SI, Lew R, Bluhmki E, Hacke W, Fisher M, (2007) Shift analysis versus dichotomization of the modified Rankin Scale outcome scores in the NINDS and ECASS-II trials. Stroke 38: 3205-3212.
11. Saver JL, (2007) Novel-end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke 38: 3055-3062.
12. Saver JL, Gornbein J, (2009) Treatment effect for which shift or binary analyses are advantageous in acute stroke trials. Neurology 72: 1310-1315.
13. Bath PMW, Lees KR, Schellinger PD, Altman H, Bland M, et al. (2012) Statistical Analysis of the Primary Outcome in Acute Stroke Trials. Stroke 43: 1171-1118.
14. Altman DG, Royston P, (2006) The cost of dichotomizing continuous variables. BMJ 332: 1080.
15. Shannon CE, Weaver W (1949) The mathematical theory of communication. Urbana IL: University of Illinois Press. Pp4-28 and 31-80.
16. Cover TM, Thomas JA (1991) Introduction and Preview. In: Elements of Information Theory. New York: John Wiley & Sons. Pp 1-11.
17. Outcomes Working Group. The Optimizing Analysis of Stroke Trials (OAST) (2007) Can We Improve the Statistical Analysis of Stroke Trials? Statistical Reanalysis of Functional Outcomes in Stroke Trials Collaboration. Stroke 38: 1911-1915.
18. Saver JL, (2011) Optimal end points for acute stroke therapy trials. Best ways to measure treatment effects of drugs and devices. Stroke 42: 2356-2362.
19. Cobo E, Secades JJ, Miras F, González JA, Saver JL, et al. (2010) Boosting the chances to improve stroke treatment. Stroke 41: 3143-3150.
20. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, et al. (2006) NXY-059 for acute ischemic stroke. N Engl J Med 354: 588-600.
21. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, et al. (2007) NXY-059 for the treatment of acute ischemic stroke. N Engl J of Med 357: 562-571.
22. IST-3 collaborative group, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, et al (2012) The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 379: 2352-2363.
23. Lai SM, Duncan PW, (2001) Stroke Recovery Profile and the Modified Rankin Assessment. Neuroepidemiology. 20: 26-30.
24. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J, (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19: 604-607.
25. Wilson JT, Hareendran A, Grant M, Baird T, Schulz UG, et al. (2002) Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin scale. Stroke 33: 2243-2246.
26. Wilson JT, Hareendran A, Hendry A, Potter J, Bone I, et al. (2005) Reliability of the modified Rankin scale across multiple raters: benefits of a structured interview. Stroke 36: 777-781.
27. Quinn TJ, Dawson J, Walters MR, Lees KR, (2009) Exploring the reliability of the modified Rankin scale. Stroke 40: 762-766.
28. Quinn TJ, Dawson J, Walters MR, Lees KR, (2008) Variability in modified Rankin scoring across a large cohort of international observers. Stroke 39: 2975-2979.
29. Quinn TJ, Macarthur K, Dawson J, Walters MR, Lees KR, (2010) Reliability of Structured Modified Rankin Scale Assessment. Stroke 41: e602.
30. Erdogmus D, Xu D, Hild II K (2010) Classification with EEC, Divergence Measures and Error Bounds. In: Principe JC Editor. Information Theoretic Learning: Renyi's Entropy and Kernel Perspectives. New York: Springer. 219-261.
31. Koziol JA, Feng AC, (2006) On the analysis and interpretation of outcome measures in stroke clinical trials: lessons from the SAINT I study of NXY-059 for acute ischemic stroke. Stroke 37: 2644-2647.
32. Howard G, Waller JL, Voeks JH, Howard VJ, Jauch EC, et al. (2012) A simple, assumption-free, and clinically interpretable approach for analysis of modified Rankin outcomes. Stroke 43: 664-669.
33. Haley EC, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, et al. (2010) Phase IIB/III trial of tenecteplase in acute ischemic stroke: Results of a prematurely terminated randomized clinical trial. Stroke 41: 707-711.
34. Hall CE, Mirski M, Palesch YY, Diringer MN, Qureshi AI, et al. (2012) Clinical Trial Design in the Neurocritical Care Unit. Neurocrit Care 1: 6-19.
35. Statistics Toolbox Users Manual. The Mathworks Corporation. Available: http://www.mathworks.com/help/stats/multcompare.html. Accessed 2013 May 29.
36. Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators (2005) Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke 36: 880-890.
37. Adams HP, Effron MB, Torner J, Dávalos A, Frayne J, et al. (2008) Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international Phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 39: 87-99.
38. Zinstok SM, Roos YB; ARTIS Investigators (2012) Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet 380;731-737.
39. Lee YS, Bae HJ, Kang DW, Lee SH, Yu K, et al. (2011) Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. Cerebrovasc Dis 32: 65-71.
40. Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z, et al. (2012) Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke 43: 630-636.
41. Camerlingo M, Salvi P, Belloni G, Gamba T, Cesana BM, et al. (2005) Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. Stroke 36: 2415-2420.
42. Lang W, Stadler CH, Poljakovic Z, (2013) Fleet D; Lyse Study Group (2013) A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke. Int J Stroke 8: 95-104.
43. Diener HC, Schneider D, Lampl Y, Bornstein NM, Kozak A, et al. (2008) DP-b99, a membrane-activated metal ion chelator, as neuroprotective therapy in ischemic stroke. Stroke 39: 1774-1778.
44. Lees KR, Bornstein N, Diener HC, Gorelick PB, Rosenberg G, et al. (2013) Results of membrane-activated chelator stroke intervention randomized trial of DP-b99 in acute ischemic stroke. Stroke 44: 580-584.
45. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, et al. (1998) Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352: 1245-1251.
46. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, et al. (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359: 1317-1329.
47. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, et al. (2008) Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 7: 299-309.
48. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, et al. (2009) Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 40: e647-656.
49. Shinohara Y, Saito I, Kobayashi S, Uchiyama S, (2009) Edaravone (radical scavenger) versus Sodium Ozagrel (anti-platelet) in cardioembolic ischemic stroke (EDO trial). Cerebrovasc Dis 27: 485-492.
50. Enlimomab Acute Stroke Trial Investigators, (2001) Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology 57: 1428-1434.
51. Franke CL, Palm R, Dalby M, Schoonderwaldt HC, Hantson L, et al. (1996) Flunarizine in stroke treatment (FIST): a double blind placebo-controlled trial in Scandinavia and the Netherlands. Acta Neurol Scand 93: 56-60.
52. The North American Glycine Antagonist in Neuroprotection (GAIN) Investigators (2000) Phase II Studies of the Glycine Antagonist GV150526 in Acute Stroke The North American Experience. Stroke 31: 358-365.
53. Dávalos A, Alvarez-Sabin J, Castillo J, Díez-Tejedor E, Ferro J, et al. (2012) Citicoline in the treatment of ischaemic stroke: an international, randomized, multicentre, placebo-controlled study (ICTUS trial). Lancet 380(9839): 349-57.
54. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, et al. (2013) Endovascular therapy after t-PA alone versus t-PA alone for stroke. N Engl J Med 368: 893-903.
55. Rosso C, Corvol JC, Pires C, Crozier S, Attal Y, et al. (2012) Intensive versus subcutaneous insulin in patients with hyperacute stroke: results from the randomized INSULINFARCT trial. Stroke 43: 2343-2349.
56. Ogawa A, Mori E, Minematsu K, Taki W, Takahashi A, et al. (2007) Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke 38: 2633-2639.
57. Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, et al. (2013) A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 368: 914-923.
58. Padma Srivastava MV, Bhasin A, Bhatia R, Garg A, Gaikwad S, et al. (2012) Efficacy of minocycline in acute ischemic stroke: a single blinded, placebo-controlled trial. Neurol India 60: 23-28.
59. Lampl Y, Zivin JA, Fisher M, Lew R, Welin L, et al. (2007) Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the Neuro Thera Effectiveness and Safety Trial-1 (NEST-1). Stroke 38: 1843-1849.
60. Zivin JA, Albers GW, Bornstein N, Chippendale T, Dahlof B, et al. (2009) Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke 40: 1359-1364.
61. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333: 1581-1587.
62. Furlan AJ, Higashida R, Wechsler L, Gent M, Rowley H, et al. (1999) Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial Prolyse in Acute Cerebral Thromboembolism. JAMA 282: 2003-2011.
63. Ciccone A, Valavassori L, Ponzio M, Ballabio E, Gasparotti R, et al. (2010) Intra-arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. J Neuro Intervent Surg 2: 74-79.
64. Ciccone A, Valavassori L, Nichelatti M, Sgoifo A, Ponzio M, et al. (2013) Endovascular treatment for acute ischemic stroke. N Engl J Med 368: 904-913.
65. Mandava P, Kalkonde YV, Rochat R, Kent TA, (2010) A matching algorithm to address imbalances in study populations: application to the National Institute of Neurological Diseases and Stroke Recombinant Tissue Plasminogen Activator acute stroke trial. Stroke 41: 765-770.
66. Mandava P, Krumpelman CS, Murthy SB, Kent TA (2012) A critical review of stroke trial analytical methodology: outcome measures, study design. In Lapchak PA and Zhang JH Editors. Translational Stroke Research: From Target Selection to Clinical Trials. New York: Springer. pp833-60.
67. Mote VL, Anderson RL, (1965) An investigation of the effect of misclassification on the properties of χ2-tests in the analysis of categorical data. Biometrika 52: 95-109.
68. Bruno A, Shah N, Lin C, Close B, Hess DC, et al. (2010) Improving modified Rankin Scale assessment with a simplified questionnaire. Stroke 41: 1048-1050.
69. Saver JL, Filip B, Hamilton S, Yanes A, Craig S, et al. (2010) Improving the reliability of stroke disability grading in clinical trials and clinical practice: the Rankin Focused Assessment (RFA). Stroke 41: 992-995.
70. Maas AIR, Braakman R, Schouten HJA, Minderhoud JM, van Zomeren AH, (1983) Agreement between physicians on assessment of outcome following severe head injury. J. Neurosurg. 58: 321-325.
71. Wilson JT, Pettigrew LEL, Teasdale GM, (1998) Structured interviews for Glasgow Outcome scale and the extended Glasgow Outcome Scale: Guidelines for their use J. Neurotrauma15: 573-585.
72. Wilson JT, Slieker FJ, Legrand V, Murray G, Stocchetti N, et al. (2007) Observer variation in the assessment of outcome in traumatic brain injury: experience from a multicenter, international randomized clinical trial. Neurosurgery 61: 123-128.
73. Norman G, Monteiro S, Salama S (2012) Sample size calculations: should the emperor's clothes be off the peg or made to measure? BMJ 345; e5278.